| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6 Canada [M. D. S.], and Department of Surgery, Vancouver Hospital & Health Sciences Centre, Vancouver, British Columbia, V5Z 3J5 Canada [M. E. G.]
Androgens are potent differentiation agents that regulate prostate-specific antigen (PSA) gene expression via the androgen receptor (AR) that binds to androgen response elements (AREs) on the PSA gene to initiate transcription. However, in the absence of androgens, PSA gene expression can become elevated. This suggests that either the AR can be activated in the absence of androgen to elevate PSA gene expression through AREs on the PSA gene or that another transcription factor acting on the PSA promoter is stimulated. We have previously shown in vivo that butyrate, a differentiation agent that causes cell cycle arrest, increases serum PSA levels in castrated animals. Therefore, to determine the mechanism of butyrate induction of PSA, we used the LNCaP human prostate cancer cell line. Northern analyses and transfection experiments using a PSA reporter plasmid demonstrated induction of PSA gene expression by butyrate in LNCaP cells. Application of the antiandrogen bicalutamide blocked the induction of PSA mRNA by butyrate, suggesting a mechanism dependent on the AR. Consistent with this conclusion, electromobility shift assays showed increased AR-ARE complex formation with nuclear extracts from butyrate-treated cells. In addition, other reporter gene constructs that contain AREs were also induced by butyrate. Western blot analysis showed an increase in nuclear levels of AR protein in cells exposed to butyrate, whereas whole cell levels remained unchanged, suggesting that butyrate causes nuclear translocation of the AR. Thus, the differentiation agent butyrate causes ligand-independent activation of the AR to increase expression of the differentiation marker PSA in human prostate cancer cells.
This article has been cited by other articles:
|
|
 |
|
  M. Jiang, Y. Ma, C. Chen, X. Fu, S. Yang, X. Li, G. Yu, Y. Mao, Y. Xie, and Y. Li Androgen-Responsive Gene Database: Integrated Knowledge on Androgen-Responsive Genes Mol. Endocrinol., November 1, 2009; 23(11): 1927 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zoubeidi, A. Zardan, E. Beraldi, L. Fazli, R. Sowery, P. Rennie, C. Nelson, and M. Gleave Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity Cancer Res., November 1, 2007; 67(21): 10455 - 10465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G D Dakubo, R L Parr, L C Costello, R B Franklin, and R E Thayer Altered metabolism and mitochondrial genome in prostate cancer J. Clin. Pathol., January 1, 2006; 59(1): 10 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, D. Akinmade, and A. W. Hamburger The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription Nucleic Acids Res., October 27, 2005; 33(18): 6024 - 6033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al. Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Prostate Cancer N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kang, A. Pirskanen, O. A. Janne, and J. J. Palvimo Involvement of Proteasome in the Dynamic Assembly of the Androgen Receptor Transcription Complex J. Biol. Chem., December 6, 2002; 277(50): 48366 - 48371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tsubaki, V. Hwa, S. M. Twigg, and R. G. Rosenfeld Differential Activation of the IGF Binding Protein-3 Promoter by Butyrate in Prostate Cancer Cells Endocrinology, May 1, 2002; 143(5): 1778 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. B. Wetherill, C. E. Petre, K. R. Monk, A. Puga, and K. E. Knudsen The Xenoestrogen Bisphenol A Induces Inappropriate Androgen Receptor Activation and Mitogenesis in Prostatic Adenocarcinoma Cells Mol. Cancer Ther., May 1, 2002; 1(7): 515 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Palter, A. B. Tavares, A. Hourvitz, J. D. Veldhuis, and E. Y. Adashi Are Estrogens of Import to Primate/Human Ovarian Folliculogenesis? Endocr. Rev., June 1, 2001; 22(3): 389 - 424. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
